Clinical Trial Update: A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) [Phase 2]

View source ↗

Summary

A Phase 2 pilot study of efgartigimod for immune-mediated thrombotic thrombocytopenic purpura (iTTP) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune-mediated Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: University of Minnesota | Conditions: Immune-mediated Thrombotic Thrombocytopenic Purpura | Phase 2 | Status: RECRUITING